Phase II multi dose study investigating the safety and efficacy of NurOwn in patients with Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

Phase II multi dose study investigating the safety and efficacy of NurOwn in patients with Amyotrophic Lateral Sclerosis (ALS)

Planning
Phase of Trial: Phase II

Latest Information Update: 10 May 2016

At a glance

  • Drugs Neurotrophic factor producing mesenchymal stem cell therapy BrainStorm Cell therapeutics (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Brainstorm Cell Therapeutics
  • Most Recent Events

    • 10 May 2016 According to a BrainStorm Cell Therapeutics media release, aApproval for this trial has been received by the Hadassah's Helsinki Committee and the Company is now awaiting the approval of the Israeli MoH.
    • 14 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top